Recruiting
Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
ClinicalTrials.gov IDNCT07021911
PhaseNot Applicable
Enrollment300
SponsorFondazione Policlinico Universitario Campus Bio-Medico
Age18 Years
SexALL
Conditions studied
Breast Cancer, Radiotherapy; Complications
About this study
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
Interventions
- Radiation: Radiotherapy — Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)
Primary outcomes
- Toxicity of Radiotherapy Treatments (Baseline, at 3, 6 month, one year from the end of radiation treatment, then yearly up to 3 years)
Eligibility information
Inclusion Criteria:
* Patients suffering from stage IV breast cancer
* Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)
* Candidates for radiation treatment (both palliative and curative).
Exclusion Criteria:
* Previous radiation treatment on the same site
* Absolute contraindications to radiotherapy
* Systemic treatment administered as part of a clinical trial
Study locations
- Radiation Oncology Department Fondazione Policlinico Campus BioMedico, Rome, Italy 00128 Italy
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.